This article on Post-Traumatic Stress Disorder (PTSD) provides a review of literature on the subject, focusing on "pharmacotherapeutic practices." From the article: "We are beginning to reap the benefits of the upsurge in multi- and single-site clinical trials with newer pharmacological agents that began in the mid-1990s. Although we eagerly await publications on large industry-sponsored trials currently in progress, this is a good time to take stock of the current and older literature on pharmacotherapy for PTSD. The two major developments are publication of guidelines on best pharmacotherapeutic practices in PTSD and recent approval by the Food and Drug Administration (FDA) of sertraline as a treatment for PTSD. [...] After a five-year hiatus, research on pharmacotherapy for PTSD began to increase in the mid-1990s. Much of this activity was spurred by the interest of pharmaceutical companies in testing the efficacy of SSRIs and related agents on patients with PTSD. Such activity has not only resulted in FDA approval of sertraline and multisite trials with other agents such as nefazadone but has also stimulated the development of new classes of drugs, such as corticotropin releasing factor antagonists, substance P antagonists, and new anticonvulsants such as lamotrigine to consider that older agents such as antiadrenergic agents, and gabapentin (see Friedman, in press) that may eventu-MAOIs [monoamine oxidase inhibitors], anticonvulsants, and possibly TCAs [tricyclic antidepressants] may yet find ally prove efficacious in PTSD. As we are swept along by their niche in PTSD pharmacotherapy after they have been this exciting momentum, however, we should not neglect evaluated systematically."
National Center for PTSD: http://www.ptsd.va.gov/
PTSD Research Quarterly (Winter 2000), v.11 no.1